These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 34112949)

  • 1. Cancer immunotherapy: it's time to better predict patients' response.
    Pilard C; Ancion M; Delvenne P; Jerusalem G; Hubert P; Herfs M
    Br J Cancer; 2021 Sep; 125(7):927-938. PubMed ID: 34112949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination strategies to maximize the benefits of cancer immunotherapy.
    Zhu S; Zhang T; Zheng L; Liu H; Song W; Liu D; Li Z; Pan CX
    J Hematol Oncol; 2021 Sep; 14(1):156. PubMed ID: 34579759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
    Appleton E; Hassan J; Chan Wah Hak C; Sivamanoharan N; Wilkins A; Samson A; Ono M; Harrington KJ; Melcher A; Wennerberg E
    Front Immunol; 2021; 12():754436. PubMed ID: 34733287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
    Meng Q; He J; Zhong L; Zhao Y
    Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
    Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
    Front Immunol; 2022; 13():961796. PubMed ID: 35911673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Perspectives in Immunotherapy for Liver Cancer.
    Lambring CB; Ghabach B; Narra K; Basha R
    Crit Rev Oncog; 2020; 25(1):31-46. PubMed ID: 32865909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
    Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond Immune Checkpoint Inhibitors: Emerging Targets in Melanoma Therapy.
    Knight AD; Luke JJ
    Curr Oncol Rep; 2024 Jul; 26(7):826-839. PubMed ID: 38789670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arenavirus Therapy in Combination with Checkpoint Blockade as an Effective Way for Better Tumour Clearance.
    Bhat H; Ali M; Hamdan TA
    Cell Physiol Biochem; 2021 Nov; 55(6):726-738. PubMed ID: 34816678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
    Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.
    Nakajima H; Nakatsura T
    Immunol Med; 2021 Mar; 44(1):10-15. PubMed ID: 32643578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK Cell-Based Immune Checkpoint Inhibition.
    Khan M; Arooj S; Wang H
    Front Immunol; 2020; 11():167. PubMed ID: 32117298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
    Chiu M; Armstrong EJL; Jennings V; Foo S; Crespo-Rodriguez E; Bozhanova G; Patin EC; McLaughlin M; Mansfield D; Baker G; Grove L; Pedersen M; Kyula J; Roulstone V; Wilkins A; McDonald F; Harrington K; Melcher A
    Expert Opin Biol Ther; 2020 Jun; 20(6):635-652. PubMed ID: 32067509
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapies and Combination Strategies for Immuno-Oncology.
    Barbari C; Fontaine T; Parajuli P; Lamichhane N; Jakubski S; Lamichhane P; Deshmukh RR
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
    Uche IK; Kousoulas KG; Rider PJF
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
    Shaver KA; Croom-Perez TJ; Copik AJ
    Front Immunol; 2021; 12():679117. PubMed ID: 33995422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.